67 related articles for article (PubMed ID: 9607567)
1. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity.
Rasouli-Nia A; Liu D; Perdue S; Britten RA
Clin Cancer Res; 1998 May; 4(5):1111-6. PubMed ID: 9607567
[TBL] [Abstract][Full Text] [Related]
2. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells.
Cheung HW; Ling MT; Tsao SW; Wong YC; Wang X
Carcinogenesis; 2004 Jun; 25(6):881-7. PubMed ID: 14742319
[TBL] [Abstract][Full Text] [Related]
3. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells.
Huang Y; Sheikh MS; Fornace AJ; Holbrook NJ
Oncogene; 1999 Jun; 18(23):3431-9. PubMed ID: 10376521
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Taxol-induced cell death are concentration dependent.
Torres K; Horwitz SB
Cancer Res; 1998 Aug; 58(16):3620-6. PubMed ID: 9721870
[TBL] [Abstract][Full Text] [Related]
5. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T
Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663
[TBL] [Abstract][Full Text] [Related]
8. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
Blagosklonny MV; Giannakakou P; el-Deiry WS; Kingston DG; Higgs PI; Neckers L; Fojo T
Cancer Res; 1997 Jan; 57(1):130-5. PubMed ID: 8988053
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
10. Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells.
Fang M; Liu B; Schmidt M; Lu Y; Mendelsohn J; Fan Z
Anticancer Res; 2000; 20(1A):103-11. PubMed ID: 10769641
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.
Ling YH; Yang Y; Tornos C; Singh B; Perez-Soler R
Cancer Res; 1998 Aug; 58(16):3633-40. PubMed ID: 9721872
[TBL] [Abstract][Full Text] [Related]
13. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
14. Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein.
Ponnathpur V; Ibrado AM; Reed JC; Ray S; Huang Y; Self S; Bullock G; Nawabi A; Bhalla K
Clin Cancer Res; 1995 Nov; 1(11):1399-406. PubMed ID: 9815937
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines.
Kurdoglu B; Cheong N; Guan J; Corn BW; Curran WJ; Iliakis G
Clin Cancer Res; 1999 Sep; 5(9):2580-7. PubMed ID: 10499636
[TBL] [Abstract][Full Text] [Related]
16. Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines.
Ho TF; Peng YT; Chuang SM; Lin SC; Feng BL; Lu CH; Yu WJ; Chang JS; Chang CC
Toxicol Appl Pharmacol; 2009 Mar; 235(2):253-60. PubMed ID: 19133282
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.
Galmarini CM; Falette N; Tabone E; Levrat C; Britten R; Voorzanger-Rousselot N; Roesch-Gateau O; Vanier-Viornery A; Puisieux A; Dumontet C
Br J Cancer; 2001 Sep; 85(6):902-8. PubMed ID: 11556844
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.
Reshkin SJ; Bellizzi A; Cardone RA; Tommasino M; Casavola V; Paradiso A
Clin Cancer Res; 2003 Jun; 9(6):2366-73. PubMed ID: 12796407
[TBL] [Abstract][Full Text] [Related]
20. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
